---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-081409"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:01:24.843359+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BioAge provides NLRP3 & APJ program timeline updates in corporate presentation

## Summary
- NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.
- Full Phase 1 SAD/MAD data for NLRP3 program anticipated in mid-2026.
- Obesity proof-of-concept data for NLRP3 program expected in second half of 2026.
- APJ agonist program (oral and parenteral) expects IND submission by end of 2026.
- Company continues to advance both programs, with no financial guidance or data results provided.

## SEC filing metadata
- accession: 0000950170-25-081409
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/0000950170-25-081409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/bioa-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-081409
- JSON: https://secwatch.observer/filing/0000950170-25-081409.json
- Plain text: https://secwatch.observer/filing/0000950170-25-081409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.